## Clinical Diagnosis This patient presents with **symptomatic systolic heart failure (HF)** with reduced ejection fraction (HFrEF): - LVEF 35% (< 40% = HFrEF) - Signs of pulmonary congestion (orthopnea, crackles, cardiomegaly on CXR) - Signs of systemic congestion (elevated JVP, ankle edema) - S3 gallop (hallmark of HF) ## Guideline-Based Initial Therapy **Key Point:** In symptomatic HFrEF, the cornerstone of therapy is **dual initiation** of an ACE inhibitor (or ARB) AND a beta-blocker, both of which have proven mortality benefit and are Class I recommendations in major guidelines (ACC/AHA, ESC, CSCI). ### Why ACE-I + Beta-Blocker? | Drug Class | Mechanism | Mortality Benefit | Timing | |---|---|---|---| | ACE Inhibitor | Blocks RAAS, reduces afterload, prevents remodeling | Yes (landmark: SOLVD, CONSENSUS) | Start early, uptitrate | | Beta-Blocker | Reduces sympathetic drive, improves diastolic function, anti-arrhythmic | Yes (landmark: CIBIS, MERIT-HF, COPERNICUS) | Start low, uptitrate | | Diuretic | Relieves congestion | No mortality benefit | Symptom relief only | | Aldosterone Antagonist | RAAS inhibition, K+ retention | Yes (landmark: RALES) | Add after ACE-I/BB established | **High-Yield:** The sequence is ACE-I/ARB → Beta-blocker → Diuretic (for symptoms) → Aldosterone antagonist (if LVEF ≤ 35% and tolerated). Do NOT start with diuretics alone or digoxin as monotherapy. ## Explanation of Correct Answer (Option 1) **Lisinopril 5 mg daily + Carvedilol 3.125 mg BD:** - **Lisinopril** = ACE inhibitor; starting dose is appropriate - **Carvedilol** = beta-blocker with alpha-blocking properties; starting dose is low and safe - Both are Class I recommendations for HFrEF - Both are uptitrated based on tolerance (target: Lisinopril 10 mg daily, Carvedilol 25 mg BD) - This combination addresses the underlying pathophysiology (RAAS + sympathetic overactivation) **Clinical Pearl:** In Indian patients with HFrEF, ACE-I is preferred over ARB as first-line unless contraindicated (cough, angioedema). Carvedilol is preferred over metoprolol or atenolol in HFrEF due to superior outcomes in the COPERNICUS trial. ## Why Diuretics Are NOT First-Line While this patient has clear signs of congestion (orthopnea, edema, crackles), **diuretics do NOT reduce mortality** — they only relieve symptoms. Starting with furosemide + spironolactone (Option 2) would be premature without first establishing ACE-I/BB therapy. ## Why Other Options Are Suboptimal **Option 3 (Nitrate + Hydralazine):** This combination has a role in: - HF with preserved ejection fraction (HFpEF) in specific populations - Patients with ACE-I/ARB intolerance - It does NOT replace ACE-I/BB in HFrEF; mortality benefit is inferior to RAAS inhibition **Option 4 (Digoxin + Chlorthalidone):** - Digoxin has NO mortality benefit in HF; it only reduces symptoms and hospitalizations - Chlorthalidone is a thiazide diuretic; diuretics alone do not address the underlying pathophysiology - This approach is outdated and not guideline-concordant for initial therapy **Mnemonic for HFrEF Initial Therapy:** **"ACE-BB-DAAD"** - **A**CE inhibitor - **C**arvedilol (or other beta-blocker) - **E**veryone gets these two first - **B**eta-blocker - **D**iuretic (if congestion) - **A**ldosterone antagonist (if LVEF ≤ 35%) - **A**rni (sacubitril/valsartan, if tolerated, replaces ACE-I) - **D**apagliflozin or empagliflozin (SGLT2i, now Class IIa for all HFrEF)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.